bioAffinity Technologies (BIAF) Accounts Payables (2021 - 2026)

bioAffinity Technologies has disclosed Accounts Payables across 6 years of filings, most recently posting $836211.0 for Q1 2026.

• In Q1 2026, Accounts Payables fell 39.47% year-over-year to $836211.0; the TTM figure through Mar 2026 stood at $836211.0 (down 39.47% YoY), while the FY2025 annual figure was $761901.0, down 22.83% from the prior year.
• Accounts Payables rose to $836211.0 in Q1 2026, from $761901.0 in the prior quarter.
• Over the last five years, Accounts Payables for BIAF reached as high as $1.4 million in Q1 2025 and fell as low as $146537.0 in Q1 2023.
• The 5-year median for Accounts Payables is $782937.0 (2024), against an average of $689378.5.
• Annual changes were most pronounced in 2023 — Accounts Payables jumped 452.09% — and 2026, when it tumbled 39.47%.
• A 5-year view of Accounts Payables shows it stood at $345042.0 in 2022, then soared by 75.28% to $604789.0 in 2023, then jumped by 63.25% to $987311.0 in 2024, then decreased by 22.83% to $761901.0 in 2025, then grew by 9.75% to $836211.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $836211.0, $761901.0, and $940761.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.